Join
Live feed
·
INSIDERFilingvia Quantisnow
Fulcrum Therapeutics Inc. logo

Amendment: Director Gould Robert J sold $163,089 worth of shares (15,000 units at $10.87), decreasing direct ownership by 3% to 469,864 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
FULC· Fulcrum Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FULC (Fulcrum Therapeutics Inc.) and more on Quantisnow.